No treatment or lifestyle program has been proven to reverse early Alzheimer’s disease. The FDA states clearly that no cure or treatment has been shown to stop or reverse the progression of the disease. But that headline answer deserves serious context, because what’s possible in the early stages is meaningfully different from what’s possible later, and several interventions can slow decline, improve cognitive scores, and in some cases produce measurable gains on brain scans.
The distinction matters because many people searching this question are really asking: “Is there still something I can do?” The answer to that question is yes, and the earlier you act, the more options you have.
What “Early Alzheimer’s” Actually Means
The term covers a spectrum. Mild cognitive impairment (MCI) sits at one end, where a person scores roughly 1 to 1.5 standard deviations below average on cognitive tests but can still manage daily life. Early-stage Alzheimer’s sits further along, where those cognitive changes are paired with biological evidence of the disease: abnormal buildup of amyloid protein in the brain, signs of nerve cell damage, or both. When both types of biomarkers are positive, clinicians assign the highest probability that Alzheimer’s is the underlying cause.
This distinction is more than academic. Some people with MCI never progress to Alzheimer’s. Others already have significant amyloid buildup but haven’t noticed major symptoms yet. The window for intervention is widest when symptoms are mild and brain damage is limited, which is why so much research focuses on this early phase.
What New Drugs Can and Can’t Do
The most publicized advances are monoclonal antibody drugs that clear amyloid plaques from the brain. These represent the first treatments that target a root biological process of the disease rather than just managing symptoms.
In its phase 3 trial, lecanemab reduced amyloid levels by about 59 centiloids (a standardized measure of plaque burden), dropping the average from 78 to roughly 19. That’s substantial clearance. Donanemab went further: about 80% of treated patients achieved complete plaque clearance on brain scans, with amyloid levels dropping by approximately 88 points from baseline.
The cognitive results, however, are more modest. Lecanemab slowed the rate of decline by 27% over 18 months compared to placebo. Donanemab slowed decline by about 35% in patients with lower levels of tau (another damaging protein). These are real, statistically significant effects. But a recent meta-analysis found that none of these drugs produced changes that exceeded the minimum clinically important difference, the threshold at which a patient or family would notice improvement in daily life. In practical terms, the benefit translates to a few extra months before symptoms worsen, not a restoration of lost abilities.
These drugs slow the disease. They do not reverse it.
Lifestyle Interventions With Real Evidence
While no single lifestyle change reverses Alzheimer’s, several produce measurable biological effects in the brain, particularly when started early.
Exercise and Brain Volume
A randomized controlled trial of 120 older adults found that moderate aerobic exercise (three days per week for one year) increased the volume of the hippocampus, the brain’s primary memory center, by about 2%. The control group, which only did stretching, saw their hippocampal volume shrink by roughly 1.4% over the same period. That 2% increase effectively reversed one to two years of age-related brain shrinkage. Participants who gained more hippocampal volume also performed better on spatial memory tests. The gains were concentrated in the anterior hippocampus, the region most vulnerable to early Alzheimer’s damage.
People with higher increases in a growth factor called BDNF (a protein that supports brain cell survival) showed the largest volume gains. While the exercise group as a whole didn’t produce significantly more BDNF than the stretching group, the individual correlation was strong: more BDNF meant more hippocampal growth.
Diet
The MIND diet, a hybrid of Mediterranean and heart-healthy eating patterns emphasizing leafy greens, berries, nuts, whole grains, and fish, has shown striking associations with Alzheimer’s risk. An analysis following participants for an average of 4.5 years found that those who adhered most closely to the MIND diet had a 53% lower rate of Alzheimer’s compared to those who didn’t follow it. Even moderate adherence was protective, though less so.
Sleep and Brain Waste Clearance
Your brain has a waste-removal system called the glymphatic system that flushes out harmful proteins, including amyloid and tau. This system is most active during deep sleep (stage 3 NREM sleep), when the spaces between brain cells expand, allowing cerebrospinal fluid to flow more freely and carry waste away. As people age, they tend to spend less time in deep sleep, which may reduce the brain’s ability to clear these damaging proteins. Poor sleep doesn’t just leave you foggy the next day. Over years, it may contribute to the protein buildup that drives Alzheimer’s.
Cognitive Training
A large NIH-funded trial found that cognitive speed training, done in sessions lasting 60 to 75 minutes twice a week over just five to six weeks, was associated with a delayed dementia diagnosis years and even decades later. Some participants received booster sessions at 11 and 35 months. Medicare data collected up to 20 years after the original training showed lasting effects. As NIH Director Jay Bhattacharya put it, “simple brain training, done for just weeks, may help people stay mentally healthy for years longer.”
Multi-Domain Programs
The most promising results come from combining multiple interventions simultaneously. The Finnish FINGER study, which bundled exercise, dietary guidance, cognitive training, and cardiovascular risk management, found that participants in the intervention group showed significant improvements in executive function (planning, problem-solving, mental flexibility) over two years compared to controls.
A similar philosophy drives the ReCODE protocol developed by Dale Bredesen, which takes a personalized approach: testing dozens of metabolic markers (inflammation levels, hormone balance, nutrient status, toxic exposures, blood sugar regulation) and addressing each one that falls outside optimal range. In a study of 255 participants, those with baseline cognitive scores of 19 or above on a standard assessment (the Montreal Cognitive Assessment) were tracked over time. Of 151 people in that group, 50% improved their scores, 23% held steady, and 27% declined. Blood glucose, inflammation markers, insulin resistance, and vitamin D levels all improved significantly in the participant pool.
These results are encouraging but come with caveats. The ReCODE study lacked a placebo control group, meaning some improvement could reflect practice effects on the test, natural fluctuation, or the placebo response. The FINGER trial was better controlled but showed benefits primarily in specific cognitive domains rather than across the board. Neither demonstrated reversal of established Alzheimer’s pathology on brain imaging.
Why “Reversal” May Be the Wrong Frame
Alzheimer’s disease involves the death of neurons. Once brain cells are gone, no current treatment brings them back. This is the core reason reversal remains out of reach. Amyloid plaques can be cleared, inflammation can be reduced, and the hippocampus can grow modestly with exercise. But the accumulated damage from years of disease progression cannot be undone.
What can happen, and what the evidence supports, is meaningful slowing. In some cases, particularly with multi-domain lifestyle approaches started during MCI or the very earliest symptomatic phase, people experience genuine improvements on cognitive tests. Whether that represents true biological reversal of early disease processes or compensation by healthy brain regions is still unclear. For the person experiencing it, the practical difference may not matter much.
The most realistic expectation for someone in the early stages is this: a combination of regular aerobic exercise, a plant-rich diet, consistent deep sleep, cognitive stimulation, and management of metabolic risk factors (blood pressure, blood sugar, inflammation) gives you the best chance of stabilizing cognitive function and extending the years you spend functioning well. If newer amyloid-clearing drugs are appropriate for your situation, they may add a modest additional benefit on top of that foundation. None of this is a cure. But it is meaningfully different from doing nothing.